PAVmed (PAVM) to Release Earnings on Thursday

PAVmed (NASDAQ:PAVM) will be releasing its earnings data before the market opens on Thursday, November 14th. Analysts expect PAVmed to post earnings of ($1.30) per share for the quarter. Persons interested in listening to the company’s earnings conference call can do so using this link.

PAVmed (NASDAQ:PAVM) last posted its earnings results on Tuesday, August 13th. The company reported ($0.84) earnings per share (EPS) for the quarter. The business had revenue of $0.98 million for the quarter. On average, analysts expect PAVmed to post $-5 EPS for the current fiscal year and $-5 EPS for the next fiscal year.

PAVmed Price Performance

PAVM stock opened at $1.12 on Wednesday. The company has a market capitalization of $11.66 million, a price-to-earnings ratio of -0.14 and a beta of 0.69. The firm has a 50 day moving average of $1.23 and a two-hundred day moving average of $1.20. PAVmed has a 12 month low of $0.60 and a 12 month high of $4.88.

Analyst Upgrades and Downgrades

Separately, Ascendiant Capital Markets cut their target price on PAVmed from $22.00 to $21.00 and set a “buy” rating on the stock in a report on Tuesday, September 10th.

About PAVmed

PAVmed Inc focuses on acquiring, developing, and commercializing novel products that target unmet needs in the United States. The company's lead products include CarpX, a patented, single-use, disposable, and minimally invasive surgical device for use in the treatment of carpal tunnel syndrome; EsoCheck Esophageal Cell Collection Device, which consists of diagnostic test that serves as a testing tool for preventing esophageal adenocarcinoma deaths, through early detection of esophageal precancer in at-risk gastroesophageal reflux disease, including chronic heartburn and acid reflux or simply reflux in patients; and EsoGuard, a bisulfite-converted next-generation sequencing DNA assay performed on surface esophageal cells collected with EsoCheck.